Literature DB >> 15753437

MTX-induced white matter changes are associated with polymorphisms of methionine metabolism.

M Linnebank1, H Pels, N Kleczar, S Farmand, K Fliessbach, H Urbach, K Orlopp, T Klockgether, I G H Schmidt-Wolf, U Schlegel.   

Abstract

Methotrexate (MTX) is a folate antagonist inhibiting nucleic acid and methionine synthesis. Methionine is necessary for CNS myelination. In 42 patients with primary CNS lymphoma (PCNSL) treated with a systemic and intraventricular high-dose MTX-based polychemotherapy, the presence of a risk haplotype defined by polymorphisms influencing methionine metabolism referred a relative risk for CNS white matter changes of 4.7 (p = 0.001). The authors conclude that methionine metabolism influences MTX neurotoxicity.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15753437     DOI： 10.1212/01.WNL.0000152840.26156.74

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  11 in total

Review 1.  Neurologic toxicities of cancer therapies.

Authors:  Robert Cavaliere; David Schiff
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

2.  Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma.

Authors:  Michael Linnebank; Susanna Moskau; Annika Jürgens; Matthias Simon; Alexander Semmler; Katjana Orlopp; Axel Glasmacher; Christopher Bangard; Marlies Vogt-Schaden; Horst Urbach; Ingo G H Schmidt-Wolf; Hendrik Pels; Uwe Schlegel
Journal:  Neuro Oncol       Date:  2008-09-19       Impact factor: 12.300

Review 3.  Genetic Modulation of Neurocognitive Development in Cancer Patients throughout the Lifespan: a Systematic Review.

Authors:  Charlotte Sleurs; Aline Madoe; Lieven Lagae; Sandra Jacobs; Sabine Deprez; Jurgen Lemiere; Anne Uyttebroeck
Journal:  Neuropsychol Rev       Date:  2019-03-30       Impact factor: 7.444

4.  The activities of antioxidant enzymes and the level of malondialdehyde in cerebellum of rats subjected to methotrexate: protective effect of caffeic acid phenethyl ester.

Authors:  Ertugrul Uzar; Hasan Rifat Koyuncuoglu; Efkan Uz; H Ramazan Yilmaz; Suleyman Kutluhan; Serkan Kilbas; Fatih Gultekin
Journal:  Mol Cell Biochem       Date:  2006-05-23       Impact factor: 3.396

5.  Intracranial tumor lysis and cerebral edema after administration of intrathecal methotrexate: a case report and discussion.

Authors:  Lohith S Bachegowda; Petros D Grivas; Rachna Anand; Elissa Stecker; Kristine Ward
Journal:  Med Oncol       Date:  2009-10-22       Impact factor: 3.064

6.  The methylenetetrahydrofolate reductase (MTHFR) variant c.677C>T (A222V) influences overall survival of patients with glioblastoma multiforme.

Authors:  Michael Linnebank; Alexander Semmler; Susanna Moskau; Yvo Smulders; Henk Blom; Matthias Simon
Journal:  Neuro Oncol       Date:  2008-05-22       Impact factor: 12.300

Review 7.  Neuropsychological sequelae of non-central nervous system cancer and cancer therapy.

Authors:  Jeffrey S Wefel; Mariana E Witgert; Christina A Meyers
Journal:  Neuropsychol Rev       Date:  2008-04-16       Impact factor: 7.444

8.  Leukoencephalopathy due to oral methotrexate.

Authors:  I González-Suárez; M J Aguilar-Amat; M Trigueros; A M Borobia; A Cruz; J Arpa
Journal:  Cerebellum       Date:  2014-02       Impact factor: 3.847

9.  Association of transcobalamin c. 776C>G with overall survival in patients with primary central nervous system lymphoma.

Authors:  M Linnebank; S Moskau; A Kowoll; A Semmler; C Bangard; M Vogt-Schaden; G Egerer; G Schackert; H Reichmann; I G H Schmidt-Wolf; H Pels; U Schlegel
Journal:  Br J Cancer       Date:  2012-10-25       Impact factor: 7.640

10.  Drug resistant epilepsy with mesial temporal sclerosis as possible late neurological complication in two AML survivors after stem cell transplantation.

Authors:  Kwan-Ming Karen Yam; Wing-Kwan Alex Leung; Xian-Lun Zhu; Lai-Wah Eva Fung
Journal:  Epilepsy Behav Case Rep       Date:  2018-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.